The next item I am looking for is the report expected by the end of Q3 from the Emergo Group regarding regulatory and reimbursement strategies for the NovoSorb BTM product currently undergoing human trials.
CZD Price at posting:
4.6¢ Sentiment: Buy Disclosure: Held